Health & Biotech Copy RSS link Link copied to clipboard!
4DMedical announces collaboration with GlaxoSmithKline
4DMedical has announced a new agreement with GlaxoSmithKline to deliver lung imaging analytics for pulmonary drug development and clinical research. The collaboration integrates with an established research data platform to provide advanced imaging biomarkers for assessing lung function. This partnership builds on an existing relationship with AstraZeneca, reinforcing the company's footprint in the pharmaceutical sector. The deal highlights growing interest in data-driven respiratory diagnostics and non-invasive lung scanning technology, despite recent share price volatility.
Sun Pharma acquires Organon for $11.75 billion amid biopharma M&A surge
On 27 April 2026, Sun Pharma announced an all-cash acquisition of Organon valued at $11.75 billion. The deal includes 70 products in women's health and general medicines, including biosimilars. This transaction occurs as the global biopharmaceutical industry faces a significant revenue decline due to the Patent Cliff, with over $200 billion in annual revenue at risk of loss of exclusivity in the US by the end of the decade. The acquisition aims to secure an established portfolio and bypass the R&D cycle.
GLP-1 agonists classified as biological medicines in EU and UK
GLP-1 receptor agonists are peptide-based medicines regulated as biological medicines in the EU, UK, and most ICH-aligned jurisdictions. In the US, the FDA classifies most as drugs under the Federal Food, Drug, and Cosmetic Act unless they meet statutory biological definitions. Injectable products with integral delivery devices are regulated as combination drug-device products. Manufacturers must verify jurisdiction-specific classifications before filing strategies to avoid delays.
UK mental health nurses describe workload as unmanageable amid patient harm risks
A Royal College of Nursing (RCN) survey reveals that specialist mental health nurses in the UK consider their workload unmanageable, with only one in five reporting manageable caseloads. The poll indicates that 51% of respondents believe patients are frequently harmed due to high caseloads and understaffing. Demand for community services rose by 38% between 2022 and 2025, while the nursing workforce grew by just 15%. The RCN calls for urgent investment, while the Department of Health and Social Care cites record funding and recruitment increases.
FDA acceleration efforts strain small biotechs
The FDA's push to accelerate drug approvals, including the National Priority Voucher pilot program and a new plausible mechanism pathway, raises challenges for smaller biotechnology companies. These firms may struggle with increased pressure to complete studies quickly and lack the financial flexibility to absorb potential trial failures. While the agency maintains that evidentiary standards remain unchanged, internal staffing issues and leadership changes create uncertainty. Experts advise companies to maintain regular communication with the FDA and document development plans carefully to navigate the shifting regulatory landscape.
Researchers present rapid multiplex molecular diagnostic systems at ESCMID conference
Global researchers presented preliminary data on new rapid molecular test systems at the European Society of Clinical Microbiology and Infectious Diseases annual conference in New York. Companies including Cepheid, SD Biosensor, Qiagen, and Diasorin showcased assays for pathogen identification and antimicrobial resistance. Presentations highlighted real-world data on workflow efficiency, cost savings, and improved diagnostic yield for conditions like meningitis and respiratory infections. Novel chemistries using CRISPR and thermal-induced switching probes were also demonstrated as potential future developments for faster, cheaper testing.
FDA and CMS announce RAPID coverage pathway for limited subset of medical devices
On April 23, 2026, the FDA and CMS announced the Regulatory Alignment for Predictable and Immediate Device (RAPID) Coverage Pathway. While aimed at accelerating coverage for breakthrough devices, eligibility is restricted to Class II devices in the Total Product Life Cycle Advisory Program or Class III devices requiring Investigational Device Exemption studies. Estimates suggest only 40 to 60 devices qualify, leaving approximately 1,000 Breakthrough Devices without accelerated coverage. CMS will issue a proposed notice for a 60-day public comment period.
Antibiotic resistance market projected to reach USD 12.72 billion by 2031
Mordor Intelligence reports the global antibiotic resistance market is estimated at USD 9.78 billion in 2026 and projected to reach USD 12.72 billion by 2031, registering a CAGR of 5.40%. Growth is driven by rising drug-resistant infections, increased investments in research, and advancements in diagnostic tools and novel therapies. Major pharmaceutical companies including Pfizer, Merck, and GlaxoSmithKline are expanding antimicrobial pipelines. The report highlights regional dynamics across North America, Europe, and Asia-Pacific.
AI-powered CRISPR-on-a-chip technology enables portable high-sensitivity diagnostics
Researchers are developing CRISPR-on-a-chip platforms combining nanoscale engineering and microfluidics for portable diagnostics. These devices, potentially integrated with smartphones, aim to detect pathogens, genetic mutations, and cancer biomarkers without a laboratory. Technologies include fluorescent reporting systems and graphene-based sensors (gFET). While fluorescent systems offer multiplexing, gFET provides extreme single-molecule sensitivity for early cancer detection. Both approaches are in early development, with potential hybrid systems expected to balance speed, cost, and sensitivity for future point-of-care use.
Eli Lilly expands dealmaking while Regeneron secures historic gene therapy approval
Eli Lilly announced significant acquisitions including Ajax Therapeutics and Kelonia Therapeutics during its upcoming Q1 earnings discussion. Concurrently, Regeneron received FDA approval for Otarmeni, the first gene therapy targeting hearing loss. The FDA also requested the removal of Amgen's Tavneos due to trial data manipulation concerns and issued priority vouchers to psychedelic developers. Sanofi and Novartis are also defending patents for Dupixent and Lutathera respectively.
AstraZeneca and Amgen join FDA effort harnessing cloud for real-time clinical trials
AstraZeneca and Amgen have agreed to pilot the FDA's new initiative for real-time clinical trials, utilizing cloud-based data repositories to stream safety signals and endpoints during drug development. AstraZeneca will test the system in its Phase 2 TRAVERSE study for mantle cell lymphoma, while Amgen will deploy it for its Phase 1b STREAM-SCLC study in small cell lung cancer. The FDA has validated data from AstraZeneca's program and opened the framework for public feedback, with final pilot participant selection expected in August. Analysts suggest this move aims to reduce structural inefficiencies and accelerate timelines.
FTSE 100 pharma giants defy policy pressures with strong start
UK pharmaceutical companies, including AstraZeneca and GSK, began the year with stronger-than-expected earnings momentum despite global policy pressures. The sector demonstrated resilience through robust performance in oncology, vaccines, and specialty medicines. While US pricing policies introduce long-term uncertainty regarding revenue models and innovation incentives, strong pipelines and defensive market characteristics support continued growth. The outlook remains cautiously optimistic as firms balance innovation with regulatory challenges.
Study finds imperfect diagnostic tests can match perfect tests for measles outbreak detection under specific conditions
Researchers simulated measles outbreak detection using stochastic SEIR models to evaluate the impact of imperfect diagnostic tests against background noise. Results indicate that with static noise, rapid diagnostic tests (RDTs) achieved 90% accuracy comparable to perfect tests. However, with dynamical noise, perfect tests outperformed RDTs (approx 90% vs <= 80%), especially when noise magnitude was high. The study concludes that surveillance system performance is highly sensitive to noise structure and magnitude, suggesting RDTs are viable in low-noise contexts but may struggle in high-dynamical noise environments.
FDA announces steps toward implementing real-time clinical trials
The US Food and Drug Administration announced steps to implement real-time clinical trials to speed up drug development. AstraZeneca and Amgen began proof of concept studies in cancer to test the initiative, reporting endpoints and safety signals to regulators as they occur. The agency aims to reduce lag time in regulatory decisions. Additionally, AbbVie secured an option to acquire Kestrel Therapeutics for up to $1.45 billion, Eli Lilly partnered with Profluent for gene editing enzymes, and GSK and Ionis received FDA acceptance for a hepatitis B drug application.
Chiesi acquires Kalvista for $1.9bn to add on-demand HAE drug
Chiesi Group has agreed to acquire Kalvista Pharmaceuticals Inc. for approximately $1.9 billion, valuing the company at $27 per share. The deal includes Kalvista's recently approved hereditary angioedema (HAE) drug, Ekterly (sebetralstat), which is the only orally available on-demand treatment for the condition. This acquisition marks Chiesi's largest to date and expands its rare disease franchise.
EMA launches pilot programme for breakthrough medical devices in EU
The European Medicines Agency (EMA) has launched a pilot programme to test a new regulatory pathway for breakthrough medical devices within the European Union. The initiative aims to accelerate patient access to highly innovative technologies while maintaining rigorous safety standards. Manufacturers of class III and class IIb devices can now request priority scientific advice. This pilot builds on guidance published by the European Commission's Medical Device Coordination Group in December 2025 and aligns with the EU Biotech Act objectives. The programme is a first step towards the formal implementation of a framework included in the December 2025 proposal for revising the Medical Devices Regulation.
Korea opens real-time infectious disease risk data to the public
The Korea Disease Control and Prevention Agency launched a public portal on Thursday to publish weekly risk assessments for over 15 infectious diseases, including Ebola and dengue fever. Previously internal data used for quarantine measures is now accessible to help travellers identify hazards and assist medical institutions in coordinating responses. The initiative aims to enhance transparency and public safety as international travel rebounds.
The Business Research Company releases outlook on antibiotics market growth to 2030
The Business Research Company has released a report forecasting the global antibiotics market to reach $115.82 billion by 2030, representing a 5.5% CAGR. The analysis highlights drivers such as antibiotic resistance, precision medicine, and emerging market growth. Key market players identified include Pfizer, Johnson & Johnson, and Roche. The report details market segmentation by drug class, spectrum, and region, alongside strategic developments like the acquisition of Paratek Pharmaceuticals and partnerships between Orchid Pharma and Cipla to combat antimicrobial resistance.
Citi raises AstraZeneca earnings forecast citing pipeline momentum
Citi has raised its earnings forecast for AstraZeneca PLC, maintaining a constructive outlook ahead of key late-stage clinical catalysts expected later in the year. The analyst upgrade reflects improved earnings expectations driven by consistent performance in oncology, cardiovascular, respiratory, and rare disease segments. Market attention remains focused on upcoming data releases from the company's diversified therapeutic pipeline, which supports long-term visibility and operational stability within the global healthcare sector.
Multidrug-resistant Enterobacterales rise in Latin America
Latin America and the Caribbean has become a global epicenter for multidrug-resistant Enterobacterales, particularly Klebsiella pneumoniae and Escherichia coli, with carbapenem resistance rates reaching up to 50% in some Colombian hospitals. The crisis is driven by fragmented healthcare systems, limited diagnostics, and the spread of high-risk clones. Clinical outcomes are severe, with bacteremia mortality reaching 40% in Argentina. Experts call for structural strategies, including improved infection prevention, environmental containment, and regional revolving funds for reserve antibiotics, rather than relying solely on new drug discovery.